Oral Cyclophosphamide for Active Scleroderma Lung Disease: A Decision Analysis

Dinesh Khanna, Daniel E. Furst, Philip J. Clements, Donald P. Tashkin and Mark H. Eckman
Additional contact information
Dinesh Khanna: Division of Rheumatology, School of Public Health, University of California at Los Angeles, dkhanna@mednet.ucla.edu, Department of Health Services, School of Public Health, University of California at Los Angeles
Daniel E. Furst: Division of Rheumatology, University of California at Los Angeles
Philip J. Clements: Division of Rheumatology, School of Public Health, University of California at Los Angeles
Donald P. Tashkin: Pulmonary Medicine and Critical Care Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles
Mark H. Eckman: Division of General Internal Medicine, Department of Medicine, University of Cincinnati, Cincinnati, Ohio, Institute for the Study of Health, University of Cincinnati, Cincinnati, Ohio

Medical Decision Making, 2008, vol. 28, issue 6, 926-937

Abstract: Background. Results from the recent Scleroderma Lung Study (SLS) show that oral cyclophosphamide (CYC) is better than placebo in preventing the progression of scleroderma-related interstitial lung disease (SSc-ILD) at 12 mo but is associated with adverse events. Also, the long-term balance of risk and benefit remains unclear. Methods. The authors evaluate the risk-benefit tradeoffs using a Markov decision analytic model to project the quality-adjusted life years (QALYs) for strategies of CYC versus no CYC in SSc-ILD. The base case examined a 50-y-old woman with SSc of 1.5 y, SSc-ILD with moderate ventilatory restriction. The authors analyze the decision to treat with 1 y of daily CYC versus no SSc-ILD — specific therapy. Based on 2-y data from the SLS, the authors assume CYC resulted in no survival benefit and only a transient beneficial impact on pulmonary function. They explore the impact of changes in model parameters through sensitivity analyses, including the efficacy of CYC in preventing progression of lung disease and SSc-ILD — related death. Results. In the base-case analysis, CYC-treated patients fared worse, with a small loss of 0.21 QALYs (16.84 v. 17.15). CYC remained inferior across sensitivity analyses for most variables. In analyses assuming a survival benefit with CYC, CYC resulted in a clinically significant gain (18.17 v. 17.15 QALYs). Conclusions. CYC therapy for 1 y results in a small loss in QALYs compared with no CYC for SSc-ILD. The lack of a beneficial impact on survival and the transience of CYC's impact on decline in pulmonary function drive this conclusion.

Keywords: Scleroderma Lung Study; scleroderma; cyclophosphamide; interstitial lung disease; pulmonary fibrosis; decision analysis. (search for similar items in EconPapers)
Date: 2008
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.sagepub.com/doi/10.1177/0272989X08317015 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:sae:medema:v:28:y:2008:i:6:p:926-937

DOI: 10.1177/0272989X08317015

Access Statistics for this article

More articles in Medical Decision Making
Bibliographic data for series maintained by SAGE Publications ().